SS-31 (Elamipretide)

The available literature on SS-31 (Elamipretide) consists entirely of narrative reviews rather than original clinical trials or controlled studies. These three moderate-quality reviews address related biological themes — mitochondrial dysfunction, oxidative stress, inflammation in aging, and conditions like dry AMD — but none directly report clinical outcome data for SS-31 itself. As a result, the evidence base drawn from this specific article set cannot support confident claims about the supplement's effects in humans. The reviews collectively suggest that mitochondrial dysfunction and reactive oxygen species (ROS) accumulation are implicated in aging-related conditions including AMD and reproductive decline. One review highlights emerging therapeutic interest in targeting mitochondrial pathways for oxidative stress and inflammation in aging, which is the mechanistic space SS-31 is designed to operate in. Another review discusses innovative treatment approaches for dry AMD, a condition with limited approved therapies. These conceptual frameworks are relevant to understanding why SS-31 is of research interest, but they do not constitute direct evidence of its effectiveness. Significant limitations apply to this entire evidence summary. None of the three sources report original human data, sample sizes, or measurable outcomes for SS-31 specifically. All are narrative reviews of moderate quality, meaning they may reflect author interpretation and are subject to selection bias. Key unknowns include SS-31's clinical efficacy in humans, its optimal dosing, long-term safety profile, and whether mechanistic benefits observed in laboratory or animal models translate to real-world health outcomes. Consumers should treat any efficacy claims about SS-31 as preliminary and not yet substantiated by robust human clinical evidence.